Actively Recruiting

Phase 2
Phase 3
Age: 2Years - 25Years
All Genders
NCT05371613

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Led by Denali Therapeutics Inc. · Updated on 2025-08-05

63

Participants Needed

32

Research Sites

279 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.

CONDITIONS

Official Title

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Who Can Participate

Age: 2Years - 25Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants aged 2 to less than 6 years (Cohort A) or 6 to less than 26 years (Cohort B)
  • Confirmed diagnosis of mucopolysaccharidosis type II (nMPS II for Cohort A; nnMPS II for Cohort B)
  • No prior enzyme replacement therapy or not on continuous ERT for 4 months before screening or on maintenance ERT with tolerance to idursulfase for at least 4 months before screening
Not Eligible

You will not qualify if you...

  • Documented mutation of other genes or genetic diagnosis causing developmental delay
  • Prior treatment with iduronate 2-sulfatase (IDS) gene therapy or stem cell therapy
  • Received any central nervous system-targeted MPS enzyme replacement therapy within 6 months before screening
  • Contraindication for lumbar punctures or magnetic resonance imaging (MRI)
  • Participation in another investigational drug study or use of investigational drug within 60 days before screening or planned use during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 32 locations

1

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States, 94609

Actively Recruiting

2

Ann and Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

3

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Actively Recruiting

4

UNC Children's Research Institute

Chapel Hill, North Carolina, United States, 27514

Actively Recruiting

5

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Actively Recruiting

6

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

7

The University of Texas Medical School at Houston

Houston, Texas, United States, 77030

Actively Recruiting

8

University of Utah, PPDS

Salt Lake City, Utah, United States, 84132

Actively Recruiting

9

Sanatorio Mater Dei

Buenos Aires, Argentina

Actively Recruiting

10

Women's and Children's Hospital

North Adelaide, Australia

Withdrawn

11

UZ Antwerpen

Antwerp, Antwerpen, Belgium, 2650

Actively Recruiting

12

Universitair Ziekenhuis Brussel

Jette, Brussels Capital, Belgium, 1090

Actively Recruiting

13

Hospital de Clínicas de Porto Alegre (HCPA) - PPDS

Porto Alegre, Brazil

Actively Recruiting

14

Instituto Fernandes Figueira

Rio de Janeiro, Brazil

Withdrawn

15

University of Alberta - Faculty of Medicine & Dentistry

Edmonton, Alberta, Canada

Actively Recruiting

16

Hospital for Sick Children

Toronto, Ontario, Canada, M5G1X8

Actively Recruiting

17

McGill University Health Center

Montreal, Quebec, Canada, H4A3J1

Actively Recruiting

18

Vseobecna Fakultni Nemocnice V Praze

Prague, Czechia, 128 08

Actively Recruiting

19

Hôpital Jeanne de Flandre

Lille, France, 59000

Actively Recruiting

20

SphinCS

Höchheim, Hochheim, Germany, 65239

Actively Recruiting

21

Medizinische Universität Lausitz - Carl Thiem

Cottbus, Germany

Actively Recruiting

22

Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia

Udine, Italy, 33100

Actively Recruiting

23

Erasmus Medical Center - Sophia Children's Hospital

Rotterdam, Rotterdam, Netherlands, 3000

Actively Recruiting

24

Hospital Universitario Vall d'Hebron

Barcelona, Barcelona, Spain, 08035

Actively Recruiting

25

Hospital Infantil Universitario Niño Jesus

Madrid, Madrid, Spain, 28009

Actively Recruiting

26

Drottning Silvias Barn Och Ungdomssjukhus

Gothenburg, Sweden, 416 85

Actively Recruiting

27

Cukurova University Medical Faculty Balcali Hospital

Adana, Turkey (Türkiye), 1330

Actively Recruiting

28

Gazi Universitesi Tip Fakultesi

Çankaya, Turkey (Türkiye), 06500

Actively Recruiting

29

Great Ormond Street Hospital for Children

London, London, United Kingdom, WC1N 3JH

Actively Recruiting

30

Birmingham Women's and Children's NHS Foundation Trust

Birmingham, United Kingdom

Actively Recruiting

31

Royal Free Hospital

London, United Kingdom, NW3 2QG

Actively Recruiting

32

Salford Royal Hospital

Salford, United Kingdom, M6 8HD

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials at Denali Therapeutics

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) | DecenTrialz